137 related articles for article (PubMed ID: 25244152)
21. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
[TBL] [Abstract][Full Text] [Related]
22. Development and Validation of an Immune-Related Prognostic Signature for Ovarian Cancer Based on Weighted Gene Coexpression Network Analysis.
An Y; Yang Q
Biomed Res Int; 2020; 2020():7594098. PubMed ID: 33381581
[TBL] [Abstract][Full Text] [Related]
23. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.
Davidson B; Espina V; Steinberg SM; Flørenes VA; Liotta LA; Kristensen GB; Tropé CG; Berner A; Kohn EC
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):791-9. PubMed ID: 16467090
[TBL] [Abstract][Full Text] [Related]
24. Identifying prognostic signature in ovarian cancer using DirGenerank.
Wang JY; Chen LL; Zhou XH
Oncotarget; 2017 Jul; 8(28):46398-46413. PubMed ID: 28615526
[TBL] [Abstract][Full Text] [Related]
25. Gene expression patterns that characterize advanced stage serous ovarian cancers.
Lancaster JM; Dressman HK; Whitaker RS; Havrilesky L; Gray J; Marks JR; Nevins JR; Berchuck A
J Soc Gynecol Investig; 2004 Jan; 11(1):51-9. PubMed ID: 14706684
[TBL] [Abstract][Full Text] [Related]
26. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.
Iglesia MD; Vincent BG; Parker JS; Hoadley KA; Carey LA; Perou CM; Serody JS
Clin Cancer Res; 2014 Jul; 20(14):3818-29. PubMed ID: 24916698
[TBL] [Abstract][Full Text] [Related]
27. Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival.
Lisowska KM; Olbryt M; Student S; Kujawa KA; Cortez AJ; Simek K; Dansonka-Mieszkowska A; Rzepecka IK; Tudrej P; Kupryjańczyk J
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1239-52. PubMed ID: 27028324
[TBL] [Abstract][Full Text] [Related]
28. Inferring active and prognostic ligand-receptor pairs with interactions in survival regression models.
Ruggeri C; Eng KH
Cancer Inform; 2014; 13(Suppl 7):67-75. PubMed ID: 25657571
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiles as prognostic markers in women with ovarian cancer.
Jochumsen KM; Tan Q; Høgdall EV; Høgdall C; Kjaer SK; Blaakaer J; Kruse TA; Mogensen O
Int J Gynecol Cancer; 2009 Oct; 19(7):1205-13. PubMed ID: 19823056
[TBL] [Abstract][Full Text] [Related]
30. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
[TBL] [Abstract][Full Text] [Related]
31. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
Wu YH; Chang TH; Huang YF; Huang HD; Chou CY
Oncogene; 2014 Jun; 33(26):3432-40. PubMed ID: 23934190
[TBL] [Abstract][Full Text] [Related]
32. The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer.
Baekelandt M; Holm R; Tropé CG; Nesland JM; Kristensen GB
Ann Oncol; 1999 Nov; 10(11):1335-41. PubMed ID: 10631462
[TBL] [Abstract][Full Text] [Related]
33. High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer.
Tan L; Sha L; Hou N; Zhang M; Ma Q; Shi C
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31152111
[TBL] [Abstract][Full Text] [Related]
34. Prognostic roles of Notch receptor mRNA expression in human ovarian cancer.
Chen C; Wang X; Huang S; Wang L; Han L; Yu S
Oncotarget; 2017 May; 8(20):32731-32740. PubMed ID: 28415574
[TBL] [Abstract][Full Text] [Related]
35. Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma.
Dai F; Zhang Y; Chen Y
Hum Pathol; 2014 Jun; 45(6):1285-93. PubMed ID: 24767251
[TBL] [Abstract][Full Text] [Related]
36. Novel gene signatures for prognosis prediction in ovarian cancer.
Bao M; Zhang L; Hu Y
J Cell Mol Med; 2020 Sep; 24(17):9972-9984. PubMed ID: 32666642
[TBL] [Abstract][Full Text] [Related]
37. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
38. G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients.
Fraungruber P; Kaltofen T; Heublein S; Kuhn C; Mayr D; Burges A; Mahner S; Rathert P; Jeschke U; Trillsch F
Front Endocrinol (Lausanne); 2021; 12():564002. PubMed ID: 33679613
[TBL] [Abstract][Full Text] [Related]
39. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract][Full Text] [Related]
40. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.
Zaid TM; Yeung TL; Thompson MS; Leung CS; Harding T; Co NN; Schmandt RS; Kwan SY; Rodriguez-Aguay C; Lopez-Berestein G; Sood AK; Wong KK; Birrer MJ; Mok SC
Clin Cancer Res; 2013 Feb; 19(4):809-20. PubMed ID: 23344261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
